With a staggering 42% of adults grappling with obesity, the GLP‑1 receptor agonists have emerged as a promising trend. However, these medications can be costly. How can employers cope with these costs and enhance employee health? This guide will show you:
- An overview of GLP‑1 drugs, which ones are approved for weight loss, and what clinical trial numbers say about effectiveness
- Obesity prevalence by state
- Plan parameters to consider